Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation

被引:1
|
作者
Tebo, Collin [1 ]
Mazer-Amirshahi, Maryann [1 ,2 ]
Wax, Paul [3 ,4 ]
Campleman, Sharan [4 ]
Boyer, Edward [5 ]
Brent, Jeffrey [6 ,7 ]
Sheth, Amit [8 ]
Daniuaityte, Raminta [9 ]
Carlson, Robert [10 ]
机构
[1] Georgetown Univ, Sch Med, Washington, DC USA
[2] MedStar Washington Hosp Ctr, Dept Emergency Med, Washington, DC USA
[3] UT Southwestern Med Sch, Houston, TX USA
[4] Amer Coll Med Toxicol, Phoenix, AZ USA
[5] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA
[6] Univ Colorado, Sch Med, Aurora, CO USA
[7] Colorado Sch Publ Hlth, Aurora, CO USA
[8] Univ South Carolina, Comp Sci & Engn, Columba, SC USA
[9] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ USA
[10] Wright State Univ, Boonshoft Sch Med, Dayton, OH USA
关键词
Synthetic cannabinoid receptor agonists; spice; medical toxicology consultation; novel psychoactive substances; emergency medicine;
D O I
10.1080/02791072.2020.1851826
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Synthetic cannabinoid receptor agonists (SCRAs) are a new class of compounds with profound psychoactive effects and potential toxicity. This study characterizes patterns in SCRA abuse using qualitative interviews with individuals receiving medical toxicology consultation. Patients with suspected exposure to a new psychoactive substance were interviewed by medical toxicologists upon presentation for acute care. Investigators collected clinical and qualitative data including knowledge, attitudes, beliefs, and practices related to psychoactive substance use. Responses were categorized by identifying themes, and statistics were generated to describe patterns of use. Overall, 69% (86) of the 124 cases of novel psychoactive substance use entered into the registry were associated with exposure to SCRAs. Most patients (68.8%) had used SCRAs at least once before the presenting episode. 47.7% considered SCRAs to be very easy to obtain, and 44.2% reported paying for the substances while 32.6% acquired it for free. Nearly half (48.8%) of patients reported their primary reason for use was to get high; a small proportion used SCRAs to avoid testing positive on drug screening (6.9%) or as an alternative to marijuana (4.6%). Findings suggest an independent and stable culture is developing around the use of SCRAs separate from their appeal as an "undetectable" alternative to marijuana.
引用
收藏
页码:207 / 214
页数:8
相关论文
共 9 条
  • [1] Characterizing trends in synthetic cannabinoid use from structured patient interviews during medical toxicology consultation
    Tebo, Collin
    Mazer-Amirshahi, Maryann
    Campleman, Sharan
    Boyer, Edward
    Brent, Jeffrey
    Sheth, Amit
    Wax, Paul
    Carlson, Robert
    [J]. CLINICAL TOXICOLOGY, 2019, 57 (10) : 923 - 924
  • [2] Clinical toxicity of synthetic cannabinoid receptor agonist use
    Manini, Alex F.
    Hoffman, Robert S.
    Stimmel, Barry
    Vlahov, David
    [J]. CLINICAL TOXICOLOGY, 2015, 53 (04) : 356 - 357
  • [3] Clinical features following analytically confirmed use of 5F-ADB, a synthetic cannabinoid receptor agonist. A report from the UK IONA study
    Elamin, Muhammad E. M. O.
    Dunn, Michael
    Dargan, Paul I.
    Wood, David M.
    Tucker, Simon
    Hill, Simon L.
    Thomas, Simon H. L.
    [J]. CLINICAL TOXICOLOGY, 2017, 55 (05) : 443 - 444
  • [4] Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study
    Hill, Simon L.
    Najafi, Javad
    Dunn, Michael
    Acheampong, Paul
    Kamour, Ashraf
    Grundlingh, Johann
    Blain, Peter G.
    Thomas, Simon H. L.
    [J]. CLINICAL TOXICOLOGY, 2016, 54 (08) : 638 - 643
  • [5] Severe clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA: a report from the Identification Of Novel psychoActive substance study (IONA)
    Najafi, Javad
    Dunn, Michael
    Hill, Simon L.
    Thomas, Simon H. L.
    [J]. CLINICAL TOXICOLOGY, 2016, 54 (04) : 405 - 405
  • [6] Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015
    Cordeiro, Samuel K.
    Daro, Ryan C.
    Seung, Hyunuk
    Klein-Schwartz, Wendy
    Kim, Hong K.
    [J]. ADDICTION, 2018, 113 (10) : 1850 - 1861
  • [7] Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service
    Waugh, Jennifer
    Najafi, Javad
    Hawkins, Leonard
    Hill, Simon L.
    Eddleston, Michael
    Vale, J. Allister
    Thompson, John P.
    Thomas, Simon H. L.
    [J]. CLINICAL TOXICOLOGY, 2016, 54 (06) : 512 - 518
  • [8] Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists. A report from the United Kingdom National Poisons Information Service (vol 54, pg 512, 2016)
    Waugh, J.
    Najafi, J.
    Hawkins, L.
    [J]. CLINICAL TOXICOLOGY, 2016, 54 (06) : 543 - 543
  • [9] Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014-2019 from a US database: prescriber and patient characteristics
    Lingvay, Ildiko
    Aroda, Vanita R.
    Honore, Julie Broe
    Ersboll, Anne S.
    Husemoen, Lise Lotte Nystrup
    Jensen, Anders Boeck
    Matthiessen, Kasper Sommer
    Kosiborod, Mikhail Naum
    [J]. JOURNAL OF DIABETES, 2023, 15 (02) : 190 - 195